Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Exploring the chemical space of orally bioavailable PROTACs
Giulia Apprato, Vasanthanathan Poongavanam, Diego García Jiménez, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 4, pp. 103917-103917
Open Access | Times Cited: 12
PROTAC technology: From drug development to probe technology for target deconvolution
Si Yan, Guangshuai Zhang, Wei Luo, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116725-116725
Closed Access | Times Cited: 10
Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety
Renshuai Zhang, Songbo Xie, Jie Ran, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 5
Closed Access | Times Cited: 9
Application and challenges of nitrogen heterocycles in PROTAC linker
Yang Li, Junfeng Qu, Lizhi Jiang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 273, pp. 116520-116520
Closed Access | Times Cited: 9
Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity
Jenny Desantis, Alessandro Bazzacco, Michela Eleuteri, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116202-116202
Open Access | Times Cited: 8
Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy
Mengxia Xu, Yuyang Yun, Changjun Li, et al.
Journal of Materials Chemistry B (2024) Vol. 12, Iss. 13, pp. 3240-3248
Closed Access | Times Cited: 6
Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024)
Debasis Das, Lingzhi Xie, Hong Jian
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 6
Selective Degradation of TEADs by a PROTAC Molecule Exhibited Robust Anticancer Efficacy In Vitro and In Vivo
Yuhang Lu, Ziqin Yan, Jiaqi Sun, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Discovery of the First Potent ROR1 Degrader for the Treatment of Non-Small Cell Lung Cancer
Jinlin Li, Lin Li, Hou Cai-yun, et al.
European Journal of Medicinal Chemistry (2025), pp. 117325-117325
Closed Access
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer
Tongchen He, Caleb Cheng, Yuanyuan Qiao, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 15
Open Access | Times Cited: 5
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs
Rohan Kalyan Rej, Srinivasa Rao Allu, Joyeeta Roy, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 494-494
Open Access | Times Cited: 5
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, et al.
Cells (2024) Vol. 13, Iss. 7, pp. 578-578
Open Access | Times Cited: 4
Radioactive ADME Demonstrates ARV-110’s High Druggability Despite Low Oral Bioavailability
Yifei He, Yuandong Zheng, Chenggu Zhu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 14277-14291
Closed Access | Times Cited: 4
Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques
Siyu Chen, Jingliang Cui, Haiyan Chen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 262, pp. 115911-115911
Closed Access | Times Cited: 13
Heterobifunctional small molecules to modulate RNA function
Sandra Kovachka, Yuquan Tong, Jessica L. Childs‐Disney, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 5, pp. 449-463
Closed Access | Times Cited: 3
Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy
Yue Song, Qing‐Qing Dong, Yi-Ke Ni, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 5739-5761
Open Access | Times Cited: 3
Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection
Lei Tian, Taotao Qiang, Xiuding Yang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 115979-115979
Closed Access | Times Cited: 8
Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment
Lianlian Fan, Weifang Tong, Anhui Wei, et al.
International Journal of Biological Macromolecules (2024) Vol. 275, pp. 133680-133680
Open Access | Times Cited: 2
Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo
Dazhao Mi, Li Cheng, Yuzhan Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116789-116789
Closed Access | Times Cited: 2
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer
Ranjan Kumar Acharyya, Rohan Kalyan Rej, Biao Hu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 19010-19037
Closed Access | Times Cited: 2
Development of an Orally Bioavailable LCK PROTAC Degrader as a Potential Therapeutic Approach to T-Cell Acute Lymphoblastic Leukemia
Jamie Jarusiewicz, Satoshi Yoshimura, Marisa Actis, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 1
Discovery of an Efficacious RET PROTAC Degrader with Enhanced Antiproliferative Activity against Resistant Cancer Cells Harboring RET Solvent-Front Mutations
Qian Zhang, Yanxiang He, Danni Rao, et al.
Journal of Medicinal Chemistry (2024) Vol. 68, Iss. 1, pp. 753-775
Closed Access | Times Cited: 1
Metabolism of new drug modalities research advances – 2023 year in review
Bin Ma, Upendra A. Argikar, Lionel Cheruzel, et al.
Drug Metabolism Reviews (2024), pp. 1-24
Closed Access
Between Theory and Practice: Computational/Experimental Integrated Approaches to Understand the Solubility and Lipophilicity of PROTACs
Andrea Venturi, Stefano Di Bona, Jenny Desantis, et al.
Journal of Medicinal Chemistry (2024)
Closed Access
To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives
Diana Castagna, Benoit Gourdet, Roland Hjerpe, et al.
Progress in medicinal chemistry (2024), pp. 61-160
Closed Access
Page 1 - Next Page

Scroll to top